77 related articles for article (PubMed ID: 8867897)
1. Antiplatelet agents affecting the interaction of Tissue Factor-Factor VIIa complex with Factor X in a continuous-flow reactor.
Gir S; Reavis R; Turitto VT; Gollamudi R
Biotechnol Appl Biochem; 1996 Feb; 23(1):63-6. PubMed ID: 8867897
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo activities of the novel antiplatelet agent alpha,alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene dihydrobromide.
Lyman BA; Bond SE; Dillingham EO; Lawrence WH; Gollamudi R
Res Commun Chem Pathol Pharmacol; 1992 Dec; 78(3):279-88. PubMed ID: 1475529
[TBL] [Abstract][Full Text] [Related]
3. Chiral resolution of alpha,alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene, a novel antiplatelet compound.
Gollamudi R; Feng ZX
Chirality; 1991; 3(6):480-3. PubMed ID: 1812959
[TBL] [Abstract][Full Text] [Related]
4. Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor.
Repke D; Gemmell CH; Guha A; Turitto VT; Broze GJ; Nemerson Y
Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7623-7. PubMed ID: 2120704
[TBL] [Abstract][Full Text] [Related]
5. Enantioselective antiplatelet actions of nipecotamides.
Gollamudi R; Feng Z; Dillingham EO; Bond SE; Han G; Salgia S
Thromb Res; 1993 Feb; 69(4):361-7. PubMed ID: 8470057
[TBL] [Abstract][Full Text] [Related]
6. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
Parlow JJ; Case BL; Dice TA; Fenton RL; Hayes MJ; Jones DE; Neumann WL; Wood RS; Lachance RM; Girard TJ; Nicholson NS; Clare M; Stegeman RA; Stevens AM; Stallings WC; Kurumbail RG; South MS
J Med Chem; 2003 Sep; 46(19):4050-62. PubMed ID: 12954058
[TBL] [Abstract][Full Text] [Related]
7. The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex.
Kohrt JT; Filipski KJ; Cody WL; Cai C; Dudley DA; Van Huis CA; Willardsen JA; Rapundalo ST; Saiya-Cork K; Leadley RJ; Narasimhan L; Zhang E; Whitlow M; Adler M; McLean K; Chou YL; McKnight C; Arnaiz DO; Shaw KJ; Light DR; Edmunds JJ
Bioorg Med Chem Lett; 2005 Nov; 15(21):4752-6. PubMed ID: 16125385
[TBL] [Abstract][Full Text] [Related]
8. Phospholipid regulates the activation of factor X by tissue factor/factor VIIa (TF/VIIa) via substrate and product interactions.
Hathcock JJ; Rusinova E; Gentry RD; Andree H; Nemerson Y
Biochemistry; 2005 Jun; 44(22):8187-97. PubMed ID: 15924438
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of stereoisomers of antithrombotic nipecotamides.
Zheng X; Day C; Gollamudi R
Chirality; 1995; 7(2):90-5. PubMed ID: 7742174
[TBL] [Abstract][Full Text] [Related]
10. Use of an oriented transmembrane protein to probe the assembly of a supported phospholipid bilayer.
Contino PB; Hasselbacher CA; Ross JB; Nemerson Y
Biophys J; 1994 Sep; 67(3):1113-6. PubMed ID: 7811922
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor.
Lindhout T; Franssen J; Willems G
Thromb Haemost; 1995 Sep; 74(3):910-5. PubMed ID: 8571320
[TBL] [Abstract][Full Text] [Related]
12. A numerical analysis of factor X activation in the presence of tissue factor--factor VIIa complex in a flow reactor.
Gir S; Slack SM; Turitto VT
Ann Biomed Eng; 1996; 24(3):394-9. PubMed ID: 8734060
[TBL] [Abstract][Full Text] [Related]
13. Preliminary in vivo studies on the platelet aggregation inhibitory activity of alpha, alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene dihydrobromide in beagle dogs.
Lawrence WH; Gollamudi R; Dillingham EO; Carter-Burks G; Tisdelle PA; Lasslo A
J Pharm Sci; 1988 May; 77(5):464-5. PubMed ID: 3411473
[No Abstract] [Full Text] [Related]
14. Antiplatelet activity of nipecotamides in experimental thrombosis in mice.
Lawrence WH; Howell RD; Gollamudi R
J Pharm Sci; 1994 Feb; 83(2):222-5. PubMed ID: 8169794
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting the interaction of tissue factor/factor VII with factor X in a heterogeneous tubular reactor.
Gemmell CH; Turitto VT; Nemerson Y
Thromb Haemost; 1991 Feb; 65(2):139-43. PubMed ID: 2053099
[TBL] [Abstract][Full Text] [Related]
16. Utilization of a continuous flow reactor to study the lipoprotein-associated coagulation inhibitor (LACI) that inhibits tissue factor.
Gemmell CH; Broze GJ; Turitto VT; Nemerson Y
Blood; 1990 Dec; 76(11):2266-71. PubMed ID: 2257300
[TBL] [Abstract][Full Text] [Related]
17. Flow dependence of factor X activation by tissue factor-factor VIIa.
Contino PB; Andree HA; Nemerson Y
J Physiol Pharmacol; 1994 Mar; 45(1):81-90. PubMed ID: 8043911
[TBL] [Abstract][Full Text] [Related]
18. Lipid-bound factor Xa regulates tissue factor activity.
Hathcock J; Rusinova E; Vaananen H; Nemerson Y
Biochemistry; 2007 May; 46(20):6134-40. PubMed ID: 17469850
[TBL] [Abstract][Full Text] [Related]
19. Phospholipid surfaces regulate the delivery of substrate to tissue factor:VIIa and the removal of product.
Hathcock JJ; Rusinova E; Andree H; Nemerson Y
Blood Cells Mol Dis; 2006; 36(2):194-8. PubMed ID: 16529959
[TBL] [Abstract][Full Text] [Related]
20. Similar molecular interactions of factor VII and factor VIIa with the tissue factor region that allosterically regulates enzyme activity.
Kelley RF; Yang J; Eigenbrot C; Moran P; Peek M; Lipari MT; Kirchhofer D
Biochemistry; 2004 Feb; 43(5):1223-9. PubMed ID: 14756558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
